Navigation Links
New Cancer Treatment Stops Aggressive Sarcomas
Date:2/24/2009

NASHVILLE, Tenn., Feb. 25 /PRNewswire/ -- After all standard treatments had failed, a new cancer treatment has stopped the growth of aggressive sarcomas in two recent patients. These results are similar to the new protocol's previous success against several cancers, including melanoma, pancreatic, colon, mesothelioma and other sarcomas.

One of the patients is an 18-year-old with malignant fibrous histiocytoma (MFH) that arose in the largest bone of his leg. The cancer spread throughout his lungs, despite aggressive surgery that replaced most of his leg with metal implants. The second patient was losing a battle with desmoplastic small round cell tumor (DSRCT), a very rare and aggressive cancer. After undergoing multiple surgical procedures and different chemotherapy regimens, the DSRCT still progressed and spread through the abdomen.

After eight weeks of the NeoPlas regimen, scans showed that both patients' cancers had stopped their growth, and some tumors actually had regressed. Additionally, both patients are tolerating the treatment well and are able to carry on normal activities. NeoPlas Innovation Director of Research Dr. Stephen B. Cantrell commented, "These are early results and not statistically valid yet. Still, the sarcomas as a group are so aggressive and uniformly fatal that being able to stop their growth and spread is very exciting. It's a major victory for these individuals, and it mirrors the success we're seeing in the great majority of patients so far." The protocol also is offered for qualifying patients with mesothelioma, colon cancer, renal (kidney) cancer, pancreatic cancer and melanoma.

This investigative treatment is a combination of lovastatin, typically used as a cholesterol lowering agent, and interferon. According to Dr. Cantrell, "The key to success has been starting with a fresh look and finding the right medicines to combine. When we have administered a precisely timed regimen of low-dose interferon with lovastatin, tumors have begun regressing, sometimes within just a few weeks."

Fatigue is the most notable side effect of NeoPlas Innovation's cancer treatment. Most patients never experience effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression). An experienced physician prescribes and monitors the outpatient treatment.

A web site, www.neoplas.org, provides answers to common questions and a screening tool. Individuals can reach NeoPlas Innovation at 615-371-8100.

    EDITORS' NOTE: For an interview with Dr. Cantrell, call 615-371-8100.

'/>"/>
SOURCE NeoPlas Innovation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
2. Breast Cancer Patients May Have a New Treatment Option When Cancer Spreads
3. Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
4. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
5. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
6. Researchers Discover Metabolite Linked to Aggressive Prostate Cancer
7. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
8. Evidence Lacking in Multivitamin Study of Womens Risk of Cancer, Heart Disease or Death, Says Natural Products Association
9. deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention
10. Breast Cancer Clinical Results Show Test Can Differentiate Normal, Early and Later Stage Cancers
11. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
Breaking Medicine News(10 mins):